Register for free to
view the full innovation profile.
Thin Film(OTF) drug delivery technology specifically aimed at paediatric patients that allows controlled, sustained and complex release patterns..
About
Scientists at Strathclyde have patented an oral thin film (OTF) drug delivery technology specifically aimed at paediatric patients that allows controlled, sustained and complex release patterns.. Approximately the size of a postage stamp, OTFs are extremely convenient to administer and dissolve quickly in a patient’s saliva, releasing active ingredients without the need for chewing or water. These characteristics mean that they are also suited to other patient types that have difficulty swallowing tablets or capsules, such as the elderly.
Key Benefits
· Simple and cost-effective to manufacture using existing technology. · Low distribution and transportation costs as they are lightweight compact medicines compared to bulky/heavy liquid bottles. · Good long term stability as they are solids and do not require excipients that may have poor paediatric toxicity. · Easy to administer as they are small, child-friendly flavoured and readily dissolve in saliva which is then reflexly swallowed by the child. · High compliance, only requiring once or twice daily dosing, and can taste mask any bitter tasting drugs which is the single largest barrier to medicines compliance in children with liquid dosage medicines. · Limited drug loading as in all OTFs is not a drawback for paediatric and geriatric applications as doses are smaller and within OTF range for opioids
Applications
· Paediatric drug delivery—an area of significant unmet need. · Geriatric drug delivery